Dimension Expands Board
This article was originally published in Scrip
Executive Summary
Dimension Therapeutics, Inc., a company developing liver-directed treatments for diverse genetic disorders, has elected of Dr Georges Gemayel, former executive vice-president of Genzyme Corporation and Arlene M. Morris, former CEO of Syndax Pharmaceuticals, to its board of directors. Dimension has also announced that Donald J. Hayden, Jr. is leaving his position as a member of the board. Previously, Gemayel was executive chair of Vascular Magnetics Inc., Syndexa, and FoldRx Pharmaceuticals, Inc (acquired by Pfizer). And Morris was previously president and CEO of Affymax, Inc.